Low-cost Enabling Technology for Image-guided Photodynamic Therapy (PDT) of Oral Cancer Cancer.

Learn more about:
Related Clinical Trial
Oral Microbioma and Oral Malignant Disease Tolerance and Benefits of Mandibular Advanced Device for Snoring and Sleep Apnea in Oropharyngeal Cancer. Radial Forearm Donor Site Closure Oral Cancer Awareness in Egypt Predictive Value of GOCCLES® Device for Early Diagnosis of Oral Potentially Malignant Disorders Therapeutic Efficacy of Quercetin Versus Its Encapsulated Nanoparticle on Tongue Squamous Cell Carcinoma Cell Line Mandibular Reconstruction Preplanning (ViPMR) the Oncogenic Potential of Salivary miRNA-93 and miRNA-412-3P in Oral Lichen Planus Patients Newer Therapeutic Targets in Head and Neck Cancers Lateral Arm Free Flap for Reconstruction of the Oral Cavity and Head and Neck Soft Tissue Defects. Improved Implant for Reconstruction Purposes After Mandibular Resection Cell-free Tumor DNA in Head and Neck Cancer Patients Exploring the Application Value of PET Molecular Imaging Targeting FAP in Oral Squamous Cell Carcinoma Exfoliated Cytology in Detection of Oral Premalignant and Malignant Lesions The Oral Microbiome in OSCC The Link Between Periodontitis, Smoking and Oral Cancer Research on Optimization and Evaluation of Oral Cancer Screening Methods Low-Cost, Portable Flexible Nasopharyngoscope in Head & Neck Cancers in Low Resource Settings Topical Aldara (Imiquimod) for Oral Cancer Diagnostic Accuracy of Salivary Gamma-synuclein in Oral Malignant and Premalignant Lesions LLL Phototherapy in Oral Lesions Resulting From Anti-neoplastic Treatment Enhancing Self Care Among Oral Cancer Survivors: The Empowered Survival Trial Understanding Non-radiotherapy-based Development of Trismus Use of Ultrasound for Measuring Size of Oral Tongue Cancers Green Tea Mouthwash on the Oral Health Status in Oral Cancer Patients Oral Cancer Screening and Education in Hong Kong Evaluating Oral Visual Inspection in the Control of Oral Cancer Inductive Toripalimab and Paclitaxel/Cisplatin on Pathological Response in Oral Squamous Cell Carcinoma Patients Effects of EMG Visual Feedback for Spinal Accessory Nerve Dysfunction After Neck Dissection: a Randomized Clinical Trial Prevention of Oral DNA Damage by Black Raspberries Inductive Camrelizumab and Apatinib for Patients With Locally Advanced and Resectable Oral Squamous Cell Carcinoma NBI in Oral Cavity Cancer Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer Chemoradiation vs Immunotherapy and Radiation for Head and Neck Cancer 18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene Photodynamic Therapy System for Patients With Refractory/Unresponsive Solid Tumors Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma A Longitudinal Study of Plasma EBV DNA in Nasopharyngeal Carcinoma From Both Endemic and Non-Endemic Patient Populations Radiation Therapy and Bortezomib and Cetuximab With or Without Cisplatin to Treat Head and Neck Cancer Physical Activities by Technology Help (PATH) Accelerated Radiotherapy and Concomitant Chemo-radiotherapy in HNSCC Very Intense Radiotherapy-Chemotherapy Regimen in Advanced HNSCC Role of Neo-adjuvant Chemotherapy in Tongue Preservation in Locally Advanced Squamous Cell Carcinoma of Oral Tongue Study of Pre-operative Combination Therapy With Mogamulizumab and Nivolumab Against Solid Cancer Patients Patient Evaluation for Head and Neck Surgery Branch Studies Complete Decongestive Therapy (CDT) for Treatment of Head and Neck Lymphedema Neoadjuvant Erbitux Based Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer Quality of Life in Patients Treated for Tongue and/or Jaw Neoplasia Before and After Speech Therapy Prospective Analysis of Robot-Assisted Surgery Assessment of the Effects of Pressors on Graft Blood Flow After Free Tissue Transfer Surgery Extended Follow-Up of Young Women in Costa Rica Who Received Vaccination Against Human Papillomavirus Types 16 and 18 and Unvaccinated Controls Clinical Evaluation of the OncAlert RAPID in Subjects Presenting for Evaluation and/or Initial Biopsy; Impact on Decision-Making Neo-adjuvant Erbitux-based Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer Cigarette Smoking and Oral Microbiota Rapamycin Therapy in Head and Neck Squamous Cell Carcinoma Therapeutic Effect Of Luteolin Natural Extract Versus Its Nanoparticles On Tongue Squamous Cell Carcinoma Cell Line The Role of Lymphangiogenesis in Head and Neck Cancer Metastasis Effectiveness of Adjuvant Radiotherapy in Small Oropharyngeal Squamous Cell Cancer and Single Lymph Node Metastasis. MSOT Using Cetuximab-800CW for Detection of Cervical Lymph Node Metastases Oral Care Protocol for the Management of Chemotherapy and Radiation Therapy-Induced Oral Mucositis Least Invasive Nonlinear Light Microscopy Study of Induction Docetaxel, Cisplatin and 5-Fluorouracil Durvalumab With Radiotherapy for Adjuvant Treatment of Intermediate Risk SCCHN Trismus Trial of Therabite vs Wooden Spatula in Head and Neck Cancer Patients Improving Access to Control of Diseases for Women IMRT Plus Cisplatin Versus Conventional Radiotherapy Plus Cisplatin in Stage III-IV HNSCC Submandibular Gland Preservation in Neck Dissection uPAR PET/CT for Staging Advanced and Localised Oral and Oropharyngeal Cancer Postoperative Radiotherapy According to Molecular Analysis of Surgical Margins of Oral and Oropharyngeal SCC Autofluorescence Detection of Oral Malignancies and Database and Biospecimen Collection to Identify Biomarkers of Head and Neck Tumor Progression The Use of Functional Confections in Promoting Oral Health The Oral Microbiome and Upper Aerodigestive Squamous Cell Cancer A Study of Neoadjuvant Bio-C/T Followed by Concurrent Bio-R/T in High-risk Locally Advanced Oral Squamous Cell Carcinoma The Study of p62/SQSTM1 as a Malignant Transformation Marker for Oral Potentially Malignant Disorders and a Prognostic Marker for Oral Squamous Cell Carcinoma Evaluation of the Photobiomodulation Using LED Lamp for Curative Treatment of Radio-induced Mucositis. Spectroscopy for Diagnostic Assessment of Oral Mucosal Lesions Wild Type p53 Adenovirus for Oral Premalignancies Acupuncture Effect on Digestion in Critically Ill Post-Operative Oral and Hypo-pharyngeal Cancer Patients Cancer Chemoprevention by Metformin Hydrochloride in Oral Potentially Malignant Lesions Cancer Chemoprevention by Metformin Hydrochloride Compared to Placebo in Oral Potentially Malignant Lesions Trial of IIb Preserving Neck Dissection Expression of Hypoxia-Inducible Factor-α in Oral Precancers and Cancers Diagnosis of Oral Precancers and Cancers Using Optic Coherence Tomography Innovative Approach to Triage Oral Precancer The Role of SDF-1/CXCR4 in Metastasis of Oral Squamous Cell Carcinoma Rehabilitation Outcomes in Head and Neck Survivors Evaluation of a Multispectral Vision Enhancement System for Assessment of Oral Mucosal Lesions The Relation of Microtubule-Associated Protein 2 and Cell Migration Sensitivity and Specificity of Serum and Salivary CYFRA21-1 in the Detection of Malignant Transformation in Oral Potentially Malignant Mucosal Lesions (Diagnostic Accuracy Study) Prosthesis Guided Speech Rehabilitation of T1/T2 Cancers of the Tongue Oral Pathology Asynchronous Telementoring Pilot Study Polarized Reflectance Spectroscopy for Oral Lesions A Study of the Effects of PEITC on Oral Cells With Mutant p53 Diagnostic Accuracy of Salivary DNA Integrity Index in Oral Malignant and Premalignant Lesions Analysis of the Variation in Caspase-8 Availability and Cleavage in Oral Squamous Cell Carcinoma The Role of microRNA-29b in the Oral Squamous Cell Carcinoma Efficacy of Optically-guided Surgery in the Management of Early-staged Oral Cancer – COOLS TRIAL Assessment of Mandibular Bone Invasion With MRI Using SWIFT Effect of FDG-PET/CT for Simulation and Radiation Treatment Planning in Oral Cancer Patients Epstein-Barr Detection in Oral Cancer Workplace Tobacco Cessation And Oral Cancer Screening Study Low-cost Enabling Technology for Image-guided Photodynamic Therapy (PDT) of Oral Cancer Cancer. Elective vs Therapeutic Neck Dissection in Treatment of Early Node Negative Squamous Carcinoma of Oral Cavity Personalized Survivor Care Plan for Oral Cancer Patients-Effects on Physical-Psychological Functions and Return-to-Work Dental Hygienists and Dentists as Providers of Oral Mucosa Screening and Brush Biopsies Effects of Mouth-opening Training on the Maximum Interincisal Opening Fluorescence-guided Surgery Using cRGD-ZW800-1 in Oral Cancer Oral State of Patients Affected by an Oral Cancer Before and After Radiotherapy – 3-years Prospective Study Erlotinib Prevention of Oral Cancer (EPOC) Oral Cancer Screening in Mumbai, India by Primary Health Care Workers Study on the Carcinogenesis of Gα12 in Oral Cancer, and the Treatment of Oral Cancer Using Ga12 Inhibitor. The Optimal Neck Treatments Strategy of Early Oral Cancer Based on Adverse Pathological Factor Study on the Carcinogenesis of SOX-9 in Oral Cancer, and Chemopreventive Possibility for the Treatment of Oral Cancer. Validation of DNA Methylation Biomarkers for Oral Cancer Detection Validation of DNA Methylation Biomarkers for Oral Cancer Detection-Follow up Study Rehabilitation Outcomes of Shoulder Function in Oral Cancer Survivors Cancer Survivors Behavior Change on Oral Cancer Patients After a Localized Behavior Change Model Intervention Expression of VEGF-C and VEGF-CR in Oral Cancers and Premalignant Lesions PET/CT and Sentinel Node in Oral Cancer Validation of DNA Methylation Biomarkers for Oral Cancer Detection Web-based Education on Oral Cancer for Primary Care Physicians in Ohio Analysis Of Sensory Recovery Of Donor Size And Quality Life In Oral Cancer Patients Using an APP in Post Oral Cancer Surgery to Affect Patients’ Needs and Quality of Life.

Brief Title

Low-cost Enabling Technology for Image-guided Photodynamic Therapy (PDT) of Oral Cancer Cancer.

Official Title

Low-cost Enabling Technology for Image-guided Photodynamic Therapy (PDT) of Oral

Brief Summary

      Oral cancer in India affects mostly those from the lower socioeconomic groups, due to a
      higher exposure to risk factors such as the use of tobacco, zarda, khaini, chewing gutka,
      mawa, and kharra, which are all dry mixtures of flavorings, areca nut flakes and powdered
      tobacco. Earlier detection of oral cancer offers the best chance for long-term survival and
      has the potential to improve treatment outcomes and make healthcare affordable. Current
      treatment options, primarily surgery and/or radiation, can be curative if cancer or dysplasia
      is caught at a sufficiently early stage. Though even in these cases treatment may be
      disfiguring with significant impact upon quality of life, and many patients do not seek
      medical attention until the disease has progressed to a point where radical operation is
      required (Stage III/IV), often entailing block dissection and removal of the entire lymphatic
      drainage of the neck. Despite the radical operation, the disease still recurs, leading to an
      overall survival rate of less than 70% of these cases. The present study evaluates
      photodynamic therapy (PDT) as an alternative intervention for early-stage malignant lesions
      of the oral cavity using a low-cost and battery-powered platform that is specifically adapted
      for low and middle-income countries (LMIC) implementation.

Detailed Description

      Study Facility:

      Pre-study Screening: Patients come to Ear, Nose, and Throat (ENT)/Oral and
      Maxillofacial/Plastic and Reconstructive surgery outpatient facilities. Typically, an ENT
      specialist handles early cases (biopsy proven malignancies), while ENT and plastic surgeons
      jointly deal with advanced cases. Patients screening will take place in outpatient
      departments. The investigator/s will interview each subject to develop a brief, relevant
      medical history and determine that all selection criteria are met. The subject will receive
      an explanation of the study objectives, possible risks and benefits of the study. After
      history evaluation of the patients, Blood work will be done to check liver functions Test.
      After the blood report and inclusion and exclusion criteria, the consultant will discuss and
      educate the patients about photosensitization and Photodynamic Therapy (PDT). If patients are
      willing to take part in the study, co-investigator will obtain a signed consent form. After
      obtaining a signed consent form, the consultant will schedule an appointment for PDT therapy.

      Procedure after enrollment: Investigators plan to enroll 30 patients with oral cancer in this
      study. The study will take place at Jawaharlal Nehru Medical College (JNMC), Aligarh. This
      timeline of procedures considers that many patients may need to travel from remote rural
      areas with poor access to transportation, so it cannot be assumed that patients have
      convenient access to return to the clinic for multiple repeated biopsies.

      Aminolevulinic Acid (ALA) preparation and administration: The FDA-approved Aminolevulinic
      Acid (ALA) from Dusa Pharmaceuticals, Inc., Wilmington, Massachusetts (MA) will be used in
      powder form. Patients will initially receive a baseline ultrasound of the oral cavity prior
      to ALA administration. In the case of potentially childbearing women, a serum pregnancy test
      will be performed before ALA administration by SD (Standard Diagnostic Inc, India) Bioline
      kit. One hour prior to ALA administration, analgesic (Aceclofenac 200mg, Intas
      Pharmaceuticals, India), anti-inflammatory drug (HifenacSR 200mg; Intas Pharmaceuticals,
      India) and antiemetic (Domperidone, Domperon, 10mg; Cadila Pharmaceuticals, Inc., India) will
      be given to patients orally to avoid nausea and pain. ALA, totaling 60 mg/kg, will be
      administered orally via three repeated doses of 20 mg/kg of ALA dissolved in either orange
      juice or a soft drink, which lowers the potential of hydrogen (pH) of the solution, at 0, 1
      and 2 hours.

      Day One: Baseline imaging; Fluorescence measurement: PpIX (Protoporphyrin IX) fluorescence
      will be recorded using 405nm excitation light delivered from an Light-Emitting Diode (LED)
      source powered by a smartphone. This is a non-invasive system. The PpIX fluorescence will be
      photographed using the camera embedded in the smartphone. The advantage of this step is that
      in the long term it will obviate the need for biopsies to establish PpIX concentrations and
      could allow for online dosimetry customized to individual patients. Three photographs will be
      taken in each subject: first photograph will be taken prior to given ALA to the patients,
      second photograph after 2-3 hours of ALA incubation, and third photograph will be taken
      immediately after PDT treatment.

      Imaging Procedure before treatment: After allowing 2-3 hours for PpIX conversion and
      accumulation in the malignant tissue, a baseline image of the tumor will be obtained using
      the smartphone PpIX imaging approach. In this clinical validation study, these PpIX
      fluorescence images will be used to make treatment decisions beyond visual guidance for
      applicator placement on the lesion.

      PDT Procedure: Immediately after the brief imaging session (approximately 5 minutes), the PDT
      treatment will proceed. Depending on the exact fractionation schedule determined, a total
      fluence of 100Joule/cm2 at the lesion surface will be delivered with an area of applicators
      or compressed applicator in for approximately 30-45 minutes. Placement will be such that the
      full extent of the lesion falls within a 1mm margin of the applicator area. Every 10 minutes,
      a 2-3 minute break is provided to the patient and the study personal will check for the
      correct placement of the probe. The clinician will conduct applicator placement with the
      assistance of a nurse as needed so that it fits tightly in contact with the active surface
      facing the lesion. Care will be required when pressing an applicator tipped light delivery
      system hard against tissue. If one press too hard and the tissue is rendered temporarily
      hypoxic, there will be no PDT effect. During therapy patients will leave their mouth closed
      around the optical fiber. Depending on the exact orientation of the lesion within the oral
      cavity a mouth guard may be used to aid applicator positioning, or if this improves patient
      comfort. Also, to aid in the stabilization of the fiber and improve patient comfort, an
      ergonomic external positioning mount may be employed to help maintain the optical fiber in
      position. Provided that care is taken that no incidental body movements during irradiation
      lead to significant shifting of movement of the applicator, patients will be able to read a
      magazine, watch television (TV) if available or other similar activities from a seated
      position. Small lesions may receive a complete treatment in this time interval, while (as
      noted above), larger lesions may require one or more additional applications. Patients will
      receive analgesic Aceclofenac, HifinacSR (200 mg); Intas Pharmaceuticals, India to avoid
      pain. Appropriate Laser safety glasses will also be provided to the patients during

      Post-treatment imaging: At the conclusion of the PDT treatment, the light delivery fiber will
      be removed and a follow-up smartphone fluorescence image will be obtained for later analysis
      of PpIX photobleaching. Patients will receive guidance on the resumption of normal
      activities. After the procedure, patient will be advised to avoid foods that are spicy, hot
      or oily for at least 6 hours and advised to take analgesic as needed Aceclofenac, HifinacSR
      (200 mg); Intas Pharmaceuticals, India. to avoid pain. Patients will also be advised to stop
      smoking and chewing tobacco products.

      Day Two to Three: Routine complete blood investigations including a liver function test (LFT)
      will be performed at 1 to 2 days following ingestion of ALA. If abnormalities are noted,
      follow-up blood work will be conducted that includes a renal function test (blood urea, serum
      creatinine, uric acid) and blood electrolytes measurement.

      Day Seven to Ten: At a follow-up examination, 7 days after treatment, an ultrasound of the
      oral cavity will be conducted to assess treatment response by lesion area (cm2) and depth
      (mm). As part of this study, ALA will also be re-administered (unless a particular patient
      had an adverse reaction to ALA in the initial treatment) so that follow-up fluorescence
      imaging can also be conducted. Again, at this stage, fluorescence imaging is included for
      validation of the procedure itself, not to decide the next steps in treatment for this
      patient cohort. However, the follow-up ultrasound will be a decision point to determine
      whether a given patient needs to undergo surgical excision of residual tumor (possibly with
      additional radio- and/or chemotherapy as determined by the clinician team), or if no residual
      disease is present, a biopsy will be conducted at the original disease site for histological
      confirmation of treatment response, and/or disease progression (development of invasive
      disease). If the radiologist reports residual tumor after the ultrasound procedure, an ENT
      surgeon will perform a biopsy and the tissue will be preserved in formalin and sent for
      histopathology assessment. The depth of necrosis evaluated from the histopathology will serve
      as endpoint for evaluating the technology. This histopathology data will also be used for
      validation of imaging to establish fluorescence contrast agreement with histologically
      confirmed malignant tissue.

      Follow-up Model: Patients who have a good response to PDT will not need to undergo surgery,
      which would compromise the excellent healing of the mucosa that has been reported with this
      modality. At the same time, patients whose disease has partial or no response to PDT will
      still receive the same standard of care (surgical excision, chemo/radiation) they would have
      if they had not enrolled in the study. It is also possible that the PDT treatment, even if
      the response was not complete, could reduce the scope of excision required in these subjects.
      Therefore at the end of the study, we will have established the utility of this technology
      without interrupting the flow of treatment/management of the patients whose disease has
      partial or no response to PDT. Regardless of the flow of this study, additional follow-up on
      all patients will be carried out at 1 month,3 months, 6 months, 9 months,12 months, and 2
      years after treatment. All patient data obtained will be appropriately de-identified as per
      local institutional guidelines before off-site analysis, which will continue throughout the

      The clinical validation study will also serve as an opportunity to gather patient data that
      will be invaluable in two capacities 1) to obtain important information immediately relevant
      to individual patient care and 2) with a mind toward sustainability, investigators will seek
      to understand cultural barriers to acceptance or compliance with the proposed PDT treatment
      that will be accounted for in outreach and training plans. The present validation study is
      not powered to make a comparison between different interventions, but rather to provide a
      validation that the safety and efficacy of the low-cost approach is equivalent to previous
      reports of PDT treatment for oral cancer in traditional medical settings at JNMC.

Study Phase

Phase 1/Phase 2

Study Type


Primary Outcome

Number of Participants With no Residual Tumor Following Photodynamic Therapy (PDT)


Oral Cancer


Photodynamic Therapy

Study Arms / Comparison Groups

 Aminolevulinic acid (ALA) and Photodynamic Therapy (PDT)
Description:  Aminolevulinic Acid (ALA) administration, Photodynamic Therapy (PDT) treatment using LED (Light-emitting diode) light source and follow-up.


* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status

Combination Product

Estimated Enrollment


Start Date

March 10, 2017

Completion Date

October 12, 2020

Primary Completion Date

October 12, 2020

Eligibility Criteria

        Inclusion Criteria:

          1. Age above 21 years, males or females

          2. Subject has read and signed a written informed consent form

          3. Subject is willing to have ALA administered and wait for 2-3 hours

          4. Subject is willing to receive red light irradiation in the mouth via the fiber
             probe/applicator and is willing to have the fiber probe/applicator in the mouth for a
             maximum time of 1 hour

          5. Subject is willing to allow investigators to take measurements using smart phone
             imaging before, during and after light treatment

          6. After the procedure, the subject is willing to avoid spicy, hot, or oily foods for at
             least 6 hours

          7. Subject willing to wear full sleeve shirt and full-length garments for couple of hours

        Exclusion Criteria:

          1. Pregnancy or nursing (ALA is a drug that belongs to FDA pregnancy category C).

          2. History of photosensitivity diseases (e.g., lupus erythematosus, porphyrias).

          3. Therapy with any photosensitizing medication, e.g., thiazides (for the treatment of
             high blood pressure), fluoroquinolones, griseofulvin, or sulfonamides (for the
             treatment of infections), sulfonylureas (for the treatment of diabetes),
             phenothiazines (for the treatment of emotional problems), and other medications
             reported to cause photosensitivity within the last 6 months.

          4. Subject is unable or unwilling to comply with the study requirements.

          5. Subject has any conditions or scars within the location of the test sites that may
             interfere with the treatment or evaluation.

          6. Allergy to porphyrins or ALA.

          7. Subject has received laser treatment within 6 months in the area of the treatment.

          8. Subject is participating in other potentially confounding research, e.g., currently
             enrolled in a clinical study of any other unapproved investigational drug or device.

          9. Any other condition or laboratory value that would, in the professional opinion of the
             investigator, potentially affect response or participation in this clinical study.

         10. Subject has inadequate organ function.

         11. Subject has co-morbid systemic illnesses or severe concurrent disease.

         12. Subject is being treated for vascular disease.

         13. Subject is an employee of the participating sites directly supervised by the

         14. Subject with invasive deep carcinoma evaluated by biopsy.

         15. Subject is currently being treated for other cancers with medical or radiation

         16. Subject has AIDS or other infectious diseases, including tuberculosis, hepatitis or
             herpetic lesions (oral herpes).

         17. Subject has oral submucous fibrosis (OSF) resulting in a patient inability to
             comfortably hold the light applicator in mouth.

         18. Subject has Human papillomavirus (HPV) positive tumor.

         19. Subject has the tumor at Oropharynx area.

         20. We will excludes the patients of the all other oral lesions at sites except: the
             gingivobuccal sulcus, cheek, floor of the mouth and tongue.




21 Years - N/A

Accepts Healthy Volunteers



Tayyaba Hasan, PhD, , 

Location Countries


Location Countries


Administrative Informations



Organization ID


Secondary IDs


Responsible Party

Principal Investigator

Study Sponsor

Massachusetts General Hospital


 Jawaharlal Nehru Medical College

Study Sponsor

Tayyaba Hasan, PhD, Principal Investigator, Massachusetts General Hospital, Boston

Verification Date

February 2021